Yes the time factor a rep has with a doc is an important mention. A lot of docs are not that fond of rep visits and if they are a busy practice they want to get back to their waiting patients. If it is a practice with no patients then the rep can visit with the doc all day but it won’t matter since that doc is writing hardly any scripts. Like you say a million times zero is 0.
Chromosome , isn't the market in Canada split between Cardiologists and Primary Care with PFE only marketing to Primary Care ? It would seem that since the R-IT trial was mostly secondary prevention CAD patients ...Cardiologists would be the main market . Primary Care have enough trouble keeping their CAD patients on Statins which are very low cost and in the case of Crestor at least ...small pills and only once a day . Secondary prevention patients ( prior MI , stroke etc ) are probably more willing to add 4 large caps to their daily med routine .
But IMHO all this is largely irrelevant to AMRN's bottom line . Their main challenge is to gain more reimbursements in the EU and ramp up sales there before US revenue declines any faster then already seen in Q1 numbers
Oakmark CEO was just on CNBC-TV talking about healthcare. He liked Centene’s new management; recall a settlement in AMRN’s past involving Hikma and a Centene subsidiary. No mention of PFE, AMRN, or HLS Therapeutics in Canada.
HLTRF currently quoted at $3.45. No chart or news provided by TD Ameritrade for that ticker symbol
Market Data 
Markets 
AI
